| Name | Galidesivir |
| Description | Galidesivir (BCX4430) is a broad-spectrum antiviral compound, an adenosine analog that inhibits viral RNA-dependent RNA polymerase (RdRp) activity.Galidesivir inhibits a wide range of RNA viral pathogens in vitro, and reduces lung infections in infected animals. |
| In vitro | Galidesivir (BCX4430) undergoes phosphorylation by cellular kinases to form a triphosphate that mimics ATP. The monophosphate nucleotide of the drug is then incorporated by viral RNA polymerases into the growing RNA chain, leading to premature chain termination[1].In inhibiting the infection of Vero cells with Yellow Fever Virus (YFV), Galidesivir demonstrates effectiveness. The EC50, as determined by the neutral red uptake assay, is 8.3 μg/ml (24.5 μM)[4]. |
| In vivo | Galidesivir (BCX4430) exhibits activity following intramuscular, intraperitoneal, and oral administration in various experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir has demonstrated pronounced efficacy[1].In a hamster model of Yellow Fever (YF), Galidesivir administered at 4 mg/kg via intraperitoneal injection twice daily for 7 days proves to be effective[3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 50 mg/mL (188.49 mM), Sonication is recommended.
|
| Keywords | RNASynthesis | RNA Synthesis | RNA polymerase | RdRp | Galidesivir | DNASynthesis | DNA Synthesis | BCX-4430 | BCX 4430 | Antiviral |
| Inhibitors Related | 5-Fluorouracil | Phenytoin sodium | Guanidine hydrochloride | Hydroxychloroquine | Hexane-1,6-diol | L-Lysine | Sodium formate | 1,4-Naphthoquinone | Adenine | Carbazole | Thymidine | Usnic Acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library |
United States
